The Wolverine stack, taken seriously
Almost everyone who runs peptides for injury ends up on the same two: BPC-157 and Thymosin β-4. The pairing has been circulating under the Wolverine name for years and it works — which is precisely why it is worth asking what it is missing.
SuperHEAL is that stack at literally four times the dose — 20 mg and 20 mg against the typical 5 and 5 — built with the full-length 43-amino-acid molecule rather than the cheap fragment, with two growth hormone secretagogues added on separate receptors and the whole thing timed to arrive alongside your own largest nightly GH pulse. And even at four times, it sits below the doses used in the only human trial anyone has run.
Why those two, and why they are not enough on their own
The two compounds are complementary rather than redundant, which is the reason the pairing became standard. Research describes BPC-157 as pro-angiogenic — growing new capillaries into tissue that needs them — and as acting on gut lining, tendon, ligament and neural tissue. Thymosin β-4 is described as handling cell migration and wound closure: getting repair cells to the site and closing what is open. One signals for the rebuild; the other moves the workforce.
What neither of them does is raise the systemic signal that drives tissue repair in the first place. They act on the site. They do not change the hormonal environment the site is repairing in — and that environment is where the largest single lever sits.
Four times, literally — and a third peptide on top
A typical Wolverine vial is 5 mg of BPC-157 and 5 mg of TB-4. Ours is 20 mg and 20 mg. That is not a fair-middle estimate or a favourable reading of a range — it is four times, on both compounds, per vial. Then it adds a third peptide at the same 20 mg loading, plus a fourth.
| Per vial | BPC-157 | TB-4 | GH secretagogues | |
|---|---|---|---|---|
| Typical Wolverine vial | 5 mg | 5 mg | none | — |
| SuperHEAL | 20 mg | 20 mg | 20 mg tesa + 6 mg ipa | 4× on both |
The uncomfortable part: everyone under-doses this stack
Four times sounds aggressive until you look at what these compounds were actually given at when anyone ran a trial. The Phase 1 study of intravenous Thymosin β-4 (RGN-352) administered ascending doses of 42, 140, 420 and 1,260 mg — daily, for fourteen days — and reported the compound generally well tolerated with mild adverse events.
Set that against a community protocol running 2 to 5 mg per week. The lowest arm of that trial delivered more Thymosin β-4 in a single day than a typical Wolverine protocol delivers in a month. Even our four-times vial sits far below the bottom of the clinical range.
An honest caveat on that comparison: RGN-352 was intravenous and this is subcutaneous, which are not equivalent routes — a subcutaneous depot releases over time rather than arriving at once, so the numbers cannot be read across directly. And animal-to-human scaling of the common preclinical dose lands around 17 mg as a single human-equivalent dose, or 5 to 10 mg weekly. That figure alone is above what most people run.
Whichever comparison you prefer, they point the same way. Community dosing for these peptides was never derived from a dose-response study — it is a number that circulated and stuck, and it sits well under anything used where the dose was chosen deliberately. Where we cannot trace a dose to a source, we would rather reason from the evidence than inherit a figure whose origin nobody can name.
Full-length TB-4, not the seven-residue fragment
This is the substitution most buyers never learn they are making. Thymosin β-4 is a 43-amino-acid protein. “TB-500” as commonly sold is Ac-LKKTETQ — a seven-residue fragment containing the active site, and dramatically cheaper to synthesise.
The fragment is not fake and it is not useless. It carries the cell migration and angiogenesis activity, which is a large share of what the molecule does, and we sell it on its own as the value option precisely because it works. But research attributes additional activity to the parts the fragment omits — actin sequestration, immune modulation, and hair follicle stem cell activation — along with slower systemic clearance, which is what makes the full molecule the right choice for once-nightly dosing.
A standard purity certificate is an HPLC measurement. It tells you what fraction of the sample is the principal peak — it does not confirm the identity of that peak. A vial of pure fragment can return an excellent purity number, because it genuinely is pure. It is simply pure something else.
Distinguishing full-length TB-4 from the fragment requires mass spectrometry, because the question is one of molecular weight rather than purity — roughly 4,963 daltons against roughly 889. That is not a subtle difference, but it is invisible to the test most vendors publish. If you are paying for full-length TB-4 anywhere, ask for HPLC and MS.
Two secretagogues, two receptors, one pulse
This is what SuperHEAL adds to the classic stack, and it is the reason the vial exists. Growth hormone is the systemic repair signal, and there are two independent ways to ask the pituitary for more of it.
Tesamorelin is a GHRH analogue — 44 amino acids, FDA-approved as Egrifta for HIV-associated lipodystrophy, which means it carries real human trial data rather than mechanism alone. Research describes it as stimulating endogenous pulsatile GH release while preserving the natural diurnal pattern, rather than replacing the hormone from outside.
Ipamorelin reaches the same outcome through a different door — a selective ghrelin receptor agonist, and research describes it as triggering GH release without the cortisol, prolactin or ACTH stimulation reported for older secretagogues. That selectivity is why the literature refers to it as the clean one.
Because the two act on separate receptor families, the literature describes their combination as producing a larger pulse than either alone — the same rationale behind the long-established CJC-1295 and ipamorelin pairing. The ipamorelin dose here sits near the top of the described clinical dose-response curve rather than at a token inclusion level.
Bedtime is not a convenience, it is the dose schedule
Growth hormone is not released evenly across the day. Research describes the largest natural pulse as occurring during deep sleep, typically in the first hours of the night. A secretagogue given at midday is asking the pituitary to work against its own rhythm. Given at bedtime, it arrives alongside the pulse the body was already going to produce and amplifies it.
Which means the repair peptides and the systemic repair signal reach the tissue in the same window — overnight, while you are not using the joint, tendon or gut lining that is trying to rebuild. The stack is timed to the body rather than to your calendar.
Four actives, 15 nightly doses
| Active | Per vial | Per dose | Role |
|---|---|---|---|
| Thymosin β-4 — full 43-AA | 20 mg | 1.33 mg | Cell migration, angiogenesis, wound closure — the complete molecule |
| BPC-157 | 20 mg | 1.33 mg | Pro-angiogenic; gut, tendon, ligament and neural tissue |
| Tesamorelin | 20 mg | 1.33 mg | GHRH analogue — pituitary GH release, physiological pulse |
| Ipamorelin | 6 mg | 400 mcg | Ghrelin-receptor agonist — second, independent GH pathway |
At roughly 235 mOsm/kg this sits slightly below plasma — a comfortable, mildly hypotonic injection despite carrying more than four milligrams of active per dose. The reason is molecular weight: peptides are large molecules, so a great deal of mass contributes very little osmotically. All four actives together account for around 10 mOsm/kg of the total. Compare that with a small-molecule product, where a fraction of the mass can drive the solution to twice plasma and sting accordingly.
The stack everyone runs, at a dose derived rather than inherited, with the whole molecule instead of the fragment — and the systemic signal the original pairing never had.
All custom blends